Tirzepatide in 2026 Q2: what changed

The second quarter of 2026 gave tirzepatide one useful long-term trial and a sharper United States argument over compounded supply. SURMOUNT-MAINTAIN showed that people who continued treatment after an initial 60-week weight-loss period kept more of the loss than those switched to placebo.^[1] The FDA then proposed keeping tirzepatide off the bulk-substances list used by 503B outsourcing facilities, while warning letters challenged both research-chemical sellers and marketers of compounded products.^[2] The licensed indications did not expand during the quarter.

The quarter's clinical result was about maintenance

SURMOUNT-MAINTAIN was published online by The Lancet on 12 May 2026. It enrolled 441 adults with obesity into a 60-week open-label period on once-weekly tirzepatide. At week 60, 378 participants were randomly assigned under double-blind conditions to continue their maximum tolerated dose of 10 mg or 15 mg, reduce to 5 mg, or switch to placebo for another 52 weeks.^[1] The design studied maintenance after a substantial treatment run. It did not test tirzepatide against placebo from the first injection.

At week 112, estimated body-weight change from the original baseline was 21.9% down in the maximum-tolerated-dose group, 16.6% down in the 5 mg group, and 9.9% down in the placebo group.^[1] Participants could receive rescue tirzepatide from week 84 if they regained more than half of the weight they had lost. Rescue treatment was used by 8% of the full-dose group, 25% of the 5 mg group, and 67% of the placebo group.^[1] Those figures make the central point clearly: continued treatment maintained more weight reduction than withdrawal, while dose reduction sat between the two.

The qualification matters. Everyone reached randomisation after 60 weeks on tirzepatide, and the trial was funded by Eli Lilly. Gastrointestinal events were the most common adverse events and were mostly mild to moderate, with most occurring during dose escalation.^[1] This is evidence about strategies tested inside a trial, not an instruction to reduce, continue, or stop a prescribed medicine. That decision belongs with the prescriber who knows the patient's response and medical history.

FDA proposed a narrower route for 503B compounding

On 30 April, the FDA proposed not adding tirzepatide, semaglutide, or liraglutide to the 503B Bulks List. A 503B outsourcing facility is a registered operation that can compound batches under a specific federal exemption. The agency said it had not identified a clinical need for those facilities to compound the three drugs from bulk substances when approved products were available.^[2] The proposal concerned one compounding pathway in the United States. It did not withdraw the approved tirzepatide products or make a final determination on the bulk list.

When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need.

The original comment deadline was 29 June. On 26 June, the FDA extended it to 30 July after a request for more time to address the clinical, public-health, and legal questions.^[3] That extension is why the correct end-of-quarter description is proposed, not decided. Readers following compounded tirzepatide in the United States should separate the 503B question from patient-specific pharmacy compounding under section 503A. The April notice did not settle every route at once.

Warning letters targeted two different sales claims

Two FDA warning letters dated 31 March were posted on 7 April, placing them in the public record during Q2. Gram Peptides offered tirzepatide, retatrutide, and bacteriostatic water for sale while labelling the products for research use only. The FDA concluded that the site's claims and sales context established an intended human drug use, and treated the tirzepatide listing as an unapproved new drug.^[4] A disclaimer did not outweigh the rest of the page. That is the useful lesson for anyone looking at grey-market tirzepatide.

The Prime Sciences letter made the same point through a coded catalogue. Its site called tirzepatide GLP1-T, described the listing as being for laboratory research, and paired that wording with human weight-loss and glucose-control claims.^[5] FDA treated the product as intended for human use. The agency did not say that approved Mounjaro or Zepbound had become unapproved. It was addressing an online seller's separate product and marketing, a distinction that gets blurred whenever all tirzepatide is discussed as if it came through one supply chain.

A third letter, issued to FITISH on 8 June, dealt with compounded product rather than a research vial. FDA said the site's pictured labels suggested FITISH was the compounder when it was not, and that claims connecting the compounded products to the active ingredients in Mounjaro and Zepbound misleadingly implied FDA approval or evaluation.^[6] The agency's direct statement was that compounded drug products are not FDA approved. An approved molecule, an unapproved research product, and a compounded preparation are three regulatory objects, even when each is sold under the word tirzepatide.

What did not change

The approved-use boundary stayed in place. The Zepbound prescribing information lists chronic weight management in adults with obesity, or overweight with at least one weight-related condition, plus moderate to severe obstructive sleep apnoea in adults with obesity.^[7] It also says coadministration with another tirzepatide-containing product or any GLP-1 receptor agonist is not recommended.^[7] Nothing published in Q2 turned the maintenance trial into a new indication or made tirzepatide a self-directed treatment.

The safety baseline also stayed recognizable. The label retains a boxed warning about thyroid C-cell tumours observed in rats and states that the relevance to humans has not been determined. It lists severe gastrointestinal reactions, acute kidney injury due to volume depletion, gallbladder disease, pancreatitis, and hypersensitivity among the warnings and precautions.^[7] A maintenance result does not cancel those considerations. Our tirzepatide safety summary keeps the trial findings beside the label rather than treating either as the whole story.

What we do not yet know

The quarter did not settle how long treatment should continue for an individual patient. SURMOUNT-MAINTAIN followed a selected group for 112 weeks and allowed rescue treatment after substantial regain.^[1] It cannot tell us what happens over five or ten years, or whether the same maintenance pattern holds in people who stopped because of adverse effects, cost, pregnancy planning, or another clinical reason. It also did not compare branded tirzepatide with a compounded preparation.

The compounding proposal was still open when June ended, so its practical effect belonged to a later quarter. The warning letters document what the named websites said and why FDA objected. They do not test the contents of every vial sold online. The defensible Q2 summary is narrower: maintenance evidence improved, the 503B bulk route came under direct challenge, and FDA drew a harder line around how unapproved and compounded products were marketed. Anyone considering tirzepatide should use a licensed clinical route and discuss the current label with a qualified healthcare professional.